Lu Alleruzzo, President and COO of Immunophotonics, spoke in Professor Schlanger’s BSBA Healthcare Management class in February.

Immunophotonics is an early stage biotechnology company engaged in the development of a proprietary drug for use in an in situ autologous cancer vaccine (inCVAX), for the potential treatment of metastatic solid tumor cancers.

Alleruzzo commented, “It’s not scientifically accurate, but for simplicity, we say it is intended to try and make you allergic to your own cancer.'”

Alleruzzo transitioned from research to big business, before receiving an MBA at The University of Missouri – Columbia. It was there he realized who he wanted to be. He wants to take technology and try to apply it to help society.